20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Medtronic plc (NYSE:MDT) intends to pursue a separation of the company's combined Patient Monitoring and Respiratory Interventions businesses (NewCo), which are part of its Medical Surgical Portfolio.
- Following the separation of NewCo, Medtronic will have a more streamlined portfolio, modestly faster organic revenue growth, increased weighted average market growth rate, and a strong balance sheet.
- In FY22, the combined business generated approximately $2.2 billion in global revenue. The combined business has a constant currency revenue growth profile and gross margin profile slightly below Medtronic overall and an operating margin profile slightly higher than Medtronic overall.
- The combined business has a global commercial footprint and a team of more than 8,000 employees worldwide.
- Medtronic expects the separation to be completed in the next 12 to 18 months, subject to the satisfaction of closing conditions.
- Just before Q1 earnings, Needham noted that CEO Geoff Martha indicated that Medtronic would seek M&A and/or divestitures to drive its weighted average market growth rate higher.
- Price Action: MDT shares are up 0.87% at $83.99 on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!